Dihexa
Synthetic hexapeptide analog of angiotensin IV. Potent hepatocyte growth factor (HGF) mimetic — binds c-Met receptor to drive synaptogenesis and neuronal connectivity. Seven orders of magnitude more potent than BDNF at promoting dendritic spine formation in vitro. Developed for Alzheimer's research at Washington State University.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- active-cancer
- pregnancy
- PMID:23439483Dihexa, a small molecule that binds HGF and promotes synaptogenesis — ACS Chem Neurosci, 2013
- PMID:25451089Angiotensin IV analog dihexa: a potential treatment for Alzheimer's disease — J Pharmacol Exp Ther, 2015
Dihexa is the most potent synaptogenesis compound identified in the literature. The in vitro data is extraordinary — dendritic spine formation at concentrations seven orders of magnitude below BDNF thresholds. The c-Met/HGF pathway is the mechanism. The problem is straightforward. No human clinical trials. No established safety profile in humans. No verified dosing protocol. The rat behavioral data shows cognitive enhancement in dementia models. Translating that to a healthy human brain is an assumption, not evidence. This compound belongs in the database as a research frontier, not a protocol recommendation.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Dihexa in a protocol matched to you